SOHO State of the Art Updates and Next Questions | Progress in Higher-Risk Myelodysplastic Syndromes

This publication has 75 references indexed in Scilit:

• Comparison of prognostication by IPSS-M, IPSS-R and AIPSS-MDS in the context of limited availability of molecular data in daily clinical practice
  Annals of Hematology, 2025
• Low‐dose decitabine plus venetoclax as post‐transplant maintenance for high‐risk myeloid malignancies
  eJHaem, 2024
• Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes
  Cancer Treatment Reviews, 2023
• How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
  Clinical Hematology International, 2022
• Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis
  Clinical Lymphoma Myeloma and Leukemia, 2022
• Diagnosis and Treatment of Myelodysplastic Syndromes
  JAMA, 2022
• A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
  iScience, 2022
• Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets
  Cell Stem Cell, 2021
• Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy
  Trends in Molecular Medicine, 2016
• Myelodysplastic syndromes
  Cancer, 2007